Clinical Trial Update: Low-dose Naltrexone for Post-COVID Fatigue Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose naltrexone for post-viral fatigue syndrome has completed; the snippet does not include results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-viral Fatigue Syndrome

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: Luis Nacul | Conditions: Post-Viral Fatigue Syndrome | Phase 2 | Status: COMPLETED